Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluvastatin Sodium

FDA-approved product (capsule, oral), marketed as Fluvastatin Sodium, Lescol, Lescol Xl.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fluvastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Familial hypercholesterolemia
  • Hypercholesterolemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluvastatin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluvastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • LATAM LOWERS LDL-C

    NCT06501443 · start 2025-02-11

    Registered record
    Registry ID
    NCT06501443
    Conditions
    Hypercholesterolaemia
    Interventions
    Usual care; KJX839
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-02-11
    Completion
    2026-11-29
    Enrolment
    520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolaemia
    InterventionUsual care; KJX839
    PhasePhase 4
    Registry statusRecruiting

  • A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

    NCT06679036 · start 2025-01-21

    Registered record
    Registry ID
    NCT06679036
    Conditions
    Advanced Unresectable or Metastatic Breast Cancer
    Interventions
    HRS-2189; Fluvustat; HRS-8080; HRS-6209; HRS-1358
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-01-21
    Completion
    2026-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Unresectable or Metastatic Breast Cancer
    InterventionHRS-2189; Fluvustat; HRS-8080; HRS-6209 +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study

    NCT06785740 · start 2024-11-01

    Registered record
    Registry ID
    NCT06785740
    Conditions
    Ischemic Stroke; TIA
    Interventions
    Statin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-11-01
    Completion
    2029-09
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke; TIA
    InterventionStatin
    PhaseNot recorded
    Registry statusRecruiting

  • Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy

    NCT06553157 · start 2024-09-01

    Registered record
    Registry ID
    NCT06553157
    Conditions
    Solid Tumors; Ototoxicity
    Interventions
    Statin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2024-09-01
    Completion
    2025-10-01
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors; Ototoxicity
    InterventionStatin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins

    NCT06262685 · start 2024-03-04

    Registered record
    Registry ID
    NCT06262685
    Conditions
    Cardiovascular Diseases; Dyslipidemias; Statin Adverse Reaction; Pharmacogenic Myopathy
    Interventions
    Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines; Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines; Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines; Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines; Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines; Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines; Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines; Standard of Care (SoC) dosing of atorvastatin; Standard of Care (SoC) dosing of simvastatin; Standard of Care (SoC) dosing of pitavastatin; Standard of Care (SoC) dosing of rosuvastatin; Standard of Care (SoC) dosing of prasavastatin; Standard of Care (SoC) dosing of lovastatin; Standard of Care (SoC) dosing of fluvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-03-04
    Completion
    2025-03-04
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Dyslipidemias; Statin Adverse Reaction; Pharmacogenic Myopathy
    InterventionPreemptive pharmacogenetic atorvastatin dose based on CPIC guidelines; Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines; Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines; Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines +10 more
    PhasePhase 4
    Registry statusUnknown

  • Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

    NCT04285749 · start 2020-11-06

    Registered record
    Registry ID
    NCT04285749
    Conditions
    Malignant Melanoma
    Interventions
    Fluvastatin; RNA-sequencing; Gene expression profiling
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2020-11-06
    Completion
    2021-04-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma
    InterventionFluvastatin; RNA-sequencing; Gene expression profiling
    PhaseEarly phase 1
    Registry statusWithdrawn

  • Drug-Drug Interaction Between Rifampin and Fluvastatin

    NCT04029584 · start 2019-04-25

    Registered record
    Registry ID
    NCT04029584
    Conditions
    Drug-drug Interaction
    Interventions
    rifampin IV; Rifadin 300Mg Capsule; Fluvastatin 20 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-04-25
    Completion
    2020-04-25
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-drug Interaction
    Interventionrifampin IV; Rifadin 300Mg Capsule; Fluvastatin 20 MG
    PhasePhase 4
    Registry statusCompleted

  • An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

    NCT03510884 · start 2018-05-31

    Registered record
    Registry ID
    NCT03510884
    Conditions
    Hypercholesterolaemia
    Interventions
    Alirocumab SAR236553 (REGN727); Rosuvastatin; Atorvastatin; Simvastatin; Pravastatin; Lovastatin; Fluvastatin; Ezetimibe; Cholestyramine; Nicotinic acid; Fenofibrate; Omega-3 fatty acids; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-05-31
    Completion
    2022-08-05
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolaemia
    InterventionAlirocumab SAR236553 (REGN727); Rosuvastatin; Atorvastatin; Simvastatin +9 more
    PhasePhase 3
    Registry statusCompleted

  • Effect of Fluvastatin on Brown Fat Activity

    NCT03189511 · start 2017-05-31

    Registered record
    Registry ID
    NCT03189511
    Conditions
    Adipose Tissue, Brown; Insulin Resistance; Clinical Trial
    Interventions
    Fluvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-31
    Completion
    2018-02-19
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdipose Tissue, Brown; Insulin Resistance; Clinical Trial
    InterventionFluvastatin
    PhasePhase 4
    Registry statusCompleted

  • Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas

    NCT02115074 · start 2014-06

    Registered record
    Registry ID
    NCT02115074
    Conditions
    Glioma
    Interventions
    Fluvastatine; Celebrex
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-06
    Completion
    2022-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioma
    InterventionFluvastatine; Celebrex
    PhasePhase 1
    Registry statusCompleted

  • Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer

    NCT01992042 · start 2014-02

    Registered record
    Registry ID
    NCT01992042
    Conditions
    Prostate Cancer
    Interventions
    Fluvastatin; Pimonidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-02
    Completion
    2016-12
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionFluvastatin; Pimonidazole
    PhasePhase 2
    Registry statusCompleted

  • A Study of LY3015014 in Participants With High Cholesterol

    NCT01890967 · start 2013-06

    Registered record
    Registry ID
    NCT01890967
    Conditions
    Hypercholesterolemia
    Interventions
    LY3015014; Placebo; Statin; Ezetimibe
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-06
    Completion
    2014-06
    Enrolment
    527

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionLY3015014; Placebo; Statin; Ezetimibe
    PhasePhase 2
    Registry statusCompleted

  • Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives

    NCT01563731 · start 2013-04

    Registered record
    Registry ID
    NCT01563731
    Conditions
    Stroke; Transient Ischemic Attack; Hypertension
    Interventions
    all approved antihypertensive drugs; all approved statins
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-04
    Completion
    2021-03-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Transient Ischemic Attack; Hypertension
    Interventionall approved antihypertensive drugs; all approved statins
    PhasePhase 4
    Registry statusCompleted

  • Statin Recapture Therapy Before Coronary Artery Bypass Grafting

    NCT01715714 · start 2012-11-07

    Registered record
    Registry ID
    NCT01715714
    Conditions
    Coronary Artery Disease
    Interventions
    Statin Recapture Therapy; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11-07
    Completion
    2020-09-27
    Enrolment
    2,630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionStatin Recapture Therapy; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan

    NCT03309618 · start 2012-11

    Registered record
    Registry ID
    NCT03309618
    Conditions
    Myocardial Infarction
    Interventions
    low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val); placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-11
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction
    Interventionlow-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val); placebo
    PhaseNot applicable
    Registry statusCompleted